Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onilcamotide - CHOSA Oncology

Next Previous
Drug Profile

Onilcamotide - CHOSA Oncology

Alternative Names: Rhoc-peptide-vaccine-RV001V; RV-001; RV-001V; RV001V - CHOSA Oncology

Latest Information Update: 01 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RhoVac
  • Developer CHOSA Oncology; Mount Sinai Health System
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 15 Feb 2023 RhoVac is now called CHOSA Oncology
  • 28 Sep 2022 Phase II development for Prostate cancer (Late-stage disease, Recurrent) is ongoing in Finland, United Kingdom, Germany, Sweden, USA, Belgium (SC) (RhoVac pipeline, September 2022)
  • 29 May 2022 Efficacy data from the BraVac phase IIb Prostate cancer trial released by RhoVac

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top